BMO Capital Markets Begins Coverage on Constellation Pharmaceuticals (NASDAQ:CNST)

Share on StockTwits

Stock analysts at BMO Capital Markets assumed coverage on shares of Constellation Pharmaceuticals (NASDAQ:CNST) in a research note issued on Monday, August 13th, MarketBeat Ratings reports. The firm set an “outperform” rating and a $19.00 price target on the stock. BMO Capital Markets’ price target indicates a potential upside of 109.94% from the stock’s previous close.

Separately, Cann initiated coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They set an “outperform” rating and a $21.00 price target for the company.

Constellation Pharmaceuticals stock traded down $1.36 during mid-day trading on Monday, hitting $9.05. The company’s stock had a trading volume of 54,300 shares, compared to its average volume of 84,694. Constellation Pharmaceuticals has a 1 year low of $8.75 and a 1 year high of $12.21.

Constellation Pharmaceuticals (NASDAQ:CNST) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($9.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($9.25). equities research analysts predict that Constellation Pharmaceuticals will post -2.88 EPS for the current year.

In related news, major shareholder Alexandria Venture Investments acquired 66,667 shares of Constellation Pharmaceuticals stock in a transaction dated Monday, July 23rd. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $1,000,005.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Anthony B. Evnin acquired 133,334 shares of Constellation Pharmaceuticals stock in a transaction dated Monday, July 23rd. The stock was bought at an average price of $15.00 per share, for a total transaction of $2,000,010.00. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 400,001 shares of company stock worth $6,000,015.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

Recommended Story: How Short Selling Works

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.